bionity.com
Apr 7, 2008
Eisai Co. Ltd has signed an exclusive licence agreement with Uppsala-based biopharmaceutical company BioArctic Neuroscience for their monoclonal antibody BAN2401, developed as a next-generation ... ... Japanese firm inputs world-leading know-how in next-generation...
[read full story]